Lisa Rojkjaer - Jan 29, 2025 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
EVP, Chief Medical Officer
Signature
/s/ Raymond Furey (Attorney-in-Fact)
Stock symbol
RIGL
Transactions as of
Jan 29, 2025
Transactions value $
$0
Form type
4
Date filed
1/31/2025, 06:47 PM
Previous filing
Mar 29, 2024
Next filing
Mar 19, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RIGL Common Stock Award $0 +19.7K $0.00 19.7K Jan 29, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Employee Stock Option (Right to Buy) Award $0 +14.8K $0.00 14.8K Jan 29, 2025 Common Stock 14.8K $22.49 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over three (3) years from February 10, 2025, with the first annual vest occurring on February 10, 2026.
F2 The shares of common stock subject to the option vest monthly over three (3) years from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continuous service to the Issuer through each such period.